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Abstract
Background: Intra-arterial (IA) administration of rt-PA for ischemic stroke has the potential for greater thrombolytic
efficacy, especially for a large thrombus in the M1 or M2 segment of the middle cerebral artery (MCA). Intracranial
hemorrhage (ICH) is a concern with IA or intravenous (IV) administration especially as the therapeutic window is
extended. However, because IA administration delivers a higher local concentration of agent, the incidence and
severity of ICH may be greater than with similar doses IV. We investigated the safety of rt-PA administration by IA
compared to IV infusion following 6 hours of MCA occlusion (MCAo) with reflow in the spontaneously
hypertensive rat (SHR).
Methods: Male SHRs were subjected to 6 hours MCAo with 18 hours reflow using a snare ligature model. They
were treated with IA saline, IA rt-PA (1, 5, 10, 30 mg/kg), or IV rt-PA (10 and 30 mg/kg) by a 10 to 60 minute
infusion beginning approximately 1 minute before reflow. The rats were recovered for 24 hours after MCAo onset
at which time Bleeding Score, infarct volume, and Modified Bederson Score were measured.
Results: Greater hemorrhagic transformation occurred with 10 and 30 mg/kg rt-PA administered IA than IV. The IV
10 mg/kg rt-PA dosage induced significantly less bleeding than did the 1 or 5 mg/kg IA groups. No significant
increase in infarct volume was observed after IA or IV treatment. Rats treated with 30 mg/kg rt-PA by either the IA
or IV route had greater neurological dysfunction compared to all other groups.
Conclusions: Administration of rt-PA by the IA route following 6 hours of MCAo results in greater ICH and worse
functional recovery than comparable dosages IV. Significantly greater bleeding was observed when the IA dose
was a tenth of the IV dose. The increased bleeding did not translate in larger infarct volumes.
Background
Currently, the only approved pharmacological treatment
for ischemic stroke is rt-PA via the intravenous (IV)
route. However, recent experience with Intra-arterial
(IA) infusion of rt-PA, alone or in combination with IV
therapy or retrieval devices at the site of thrombus
formation may provide a recanalization advantage over
IV administration, especially in cases of high clot burden
such as a thrombus located in the M1 or M2 segment of
the middle cerebral artery [1-3]. IA administration of
therapeutic agents within the first 3 hours of stroke
symptom onset in the clinic is feasible [4,5] and is
required for direct-acting fibrinolytic agents in develop-
ment [6]. Although IA administration of a thrombolytic
may improve the recanalization rate, such local infusion
of agent may also increase the risk of intracerebral
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dow is extended [8]. Treatment with IV rtPA is effective
when administered within 3 hours of stroke onset [9],
but this narrow therapeutic window limits patient elig-
ibility for thrombolytic therapy; estimated at only 1-2%
[10]. Recently, the therapeutic window for IV r-tPA
treatment was extended to 4.5 hours in Europe [11,12]
and there is an ongoing clinical study aimed at further
extending this window to 6 hours [13].
T h es a f e t yo fI Ar t - P Aa d m i n i s t r a t i o nf o l l o w i n g
extended ischemic durations with respect to IV adminis-
tration has not been heretofore evaluated. In this report,
we compare IA- versus IV-delivered rt-PA in a pre-clini-
cal model in rats that mimics the clinical situation.
Methods
Animals
Adult male spontaneously hypertensive rats (SHR)
weighing 330 - 380 g were pur c h a s e df r o mt h eC h a r l e s
River Research facilities, Raleigh, NC. Animal experi-
ments were conducted at facilities located at the North
Carolina State University (NCSU) College of Agriculture
and Life Sciences (CALS). The animal use protocol was
reviewed and approved by the NCSU IACUC prior to
the initiation of the studies and was performed in com-
pliance with standards set forth by the National
Research Council publication, G u i d ef o rt h eC a r ea n d
Use of Laboratory Animals.
Upon arrival, the rats were assigned a number by the
animal facility staff and housed individually. They were
allowed at least one week to acclimate. The rats were on a
12 hour light/dark diurnal cycle and food and water were
provided ad libitum. To conserve test article, rats were
assigned to experimental groups in tandem (2 rats to the
same group/experimental day) as outlined in Table 1.
General animal preparation
All rats were fasted overnight to provide a low consis-
tent plasma glucose concentration before surgery. The
rats were anesthetized with isoflurane (5% in O2)i na n
induction chamber and orotracheally intubated. For pain
relief, all rats received 0.03 mg/kg buprenorphine, subQ
(PharmaForce, Inc., Columbus, Ohio). Anesthesia was
maintained by spontaneous ventilation of isoflurane
(1.5-3% in O2). The ventral tail artery was cannulated
(RPT-037, RenaPulse tubing, Braintree Scientific, Inc.,
Braintree MA or PE50 tubing) by cutdown. The arterial
line was used to continuously monitor blood pressure
and heart rate (Ponemah Physiological Monitoring Sys-
tem, DSI, Cleveland, Ohio) and to obtain arterial blood
for blood gas determinations (i-Stat, Heska AG, Switzer-
land). Following arterial catheterization, the rats were
artificially ventilated to maintain PaCO2 between 35 and
45 mmHg. Continued isoflurane anesthesia (1-1.5%) was
driven by compressed air supplemented with O2 to
maintain PaO2 between 95 to 170 mmHg. Body tem-
perature was maintained at or slightly above 37°C using
a heat lamp in a feedback circuit with a rectal tempera-
ture probe (TCAT-2 Temperature Controller, Physitemp
Instruments, Inc., Clifton, NJ). Just before MCAo,
reflow, and during the blood flow studies, the isoflurane
was reduced to approximately 1% (from 1.5%) to allow
for normalization of blood pressure while maintaining
an adequate level of anesthesia.
Blood flow measurements
Rats were placed in dorsal recumbency and the common
carotid (CCA), external carotid (ECA), internal carotid
(ICA), occipital and pterygopalatine arteries were iso-
lated by cutdown. A perivascular blood flow probe
(Transonic Systems Inc., Ithaca, NY) was placed around
the CCA for continuous blood flow monitoring. Sequen-
tially, the occipital, the external carotid, and the pterygo-
palatine arteries were occluded leaving the blood flow to
the brain via the extra-cranial internal carotid artery
(EC-ICA).
Transient middle cerebral artery occlusion (MCAo) model
Six (6) hours of transient MCAo was induced in the
SHR using the snare ligature model first described in
Table 1 Experimental groups and dosing details
Group n Dose [Test Article] Injection Volume Infusion Duration
Saline 5 Dose Vol — 1 μL/g BW 10 min
Vehicle 5 Dose Vol — 1 μL/g BW 10 min
rt-PA, IA Infusion 5 1 mg/kg 1 mg/mL 1 μL/g BW 10 min
7 5 mg/kg 5 mg/mL 1 μL/g BW 10 min
5 10 mg/kg 5 mg/mL 2 μL/g BW 20 min
5 30 mg/kg 5 mg/mL 6 μL/g BW 60 min
rt-PA, IV Infusion 5 10 mg/kg 5 mg/mL 2 μL/g BW 20 min
5 30 mg/kg 5 mg/mL 6 μL/g BW 60 min
The infusion rate of the test article depended on the body weight (BW) of the rat. The total volumes infused averaged 0.35 mL, 0.7 mL and 1.95 mL for infusion
durations of 10, 20 and 60 minutes, respectively.
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Page 2 of 14mice [14], adapted to the rat [15] and illustrated in Fig-
ure 1. The head was immobilized in a specially designed
head holder and a skin incision was made between the
eye and the external auditory canal. Using a surgical
microscope (Zeiss OPMI-6C, Prescott’s Inc., Monument,
CO), the temporalis muscle was bisected and retracted
and a small craniotomy was performed using a dental
drill anteromedial to the zygomatic arch-squamosal
bone junction. The dura was opened and the MCA was
isolated from the arachnoid and pia by blunt dissection
proximal to the inferior cerebral vein. The snare ligature
was constructed as illustrated in Figure 1A using a
strand of 10-0 nylon suture, a piece of 6-0 prolene
monofilament and silastic tubing (ID 0.76 mm × OD
1.65 mm × ~1 mm h; Dow Corning Corporation). The
MCA was gently pulled into the lumen of the silastic
tubing resulting in occlusion of the artery (Figure 1B).
MCAo was visually confirmed through the surgical
microscope (40 × magnification). A piece of Gelfoam
®
was placed in the cranial deficit and the surgical site
was closed in two layers. The rat was recovered from
anesthesia, extubated and returned to a clean cage. The
normal bedding in the cage was replaced with an absor-
bent cage pad (Recovery Pad ™,B e dO ’ Cobs/The
Andersons, Distributor: Granville Milling Co., Creed-
moor, NC). Between the MCAo surgery and the removal
of the snare ligature, the rats had free access to gel style
food (Hydro Gel and Diet Gel-Recovery; H2O, Portland,
Maine). The location of the snare ligature, distal to the
lenticulostrate arteries but proximal to the inferior cere-
bral vein, resulted in nearly pure cortical infarction
(Additional file 1, Figure S1).
We chose the rat snare ligature model of MCAo to
strictly control the ischemic duration which is not possible
in a thromboembolic model. Further, in a thromboembolic
model, control groups such as saline and vehicle become
de facto permanent occlusion animals and thus a proper
control for specific ischemic durations with reflow is not
practicable. In addition, the snare ligature model allows
for the initiation of local IA dosing to immediately precede
reflow. Thus, the drug would be in high concentration
during the first pass of blood into the ischemic tissue
thereby better mimicking human thrombolytic treatment
by IA administration. This is not possible using an intra-
luminal model where a significant delay between reflow
and IA dosing would occur due to exchanging the occlud-
ing filament for the dosing catheter. This is in addition to
other complications associated with the intraluminal
model such as pre-mature reflow [16], ischemia to the
hypothalamus resulting in hyperthermia [17], distension of
the MCA (personal observations) and the possibility of
filament related subarachnoid hemorrhage [16].
rt-PA dosing solution preparation
Lyophilized rt-PA (Alteplase, recombinant, Genentech,
South San Francisco, CA, USA) was solubilized at an
Figure 1 Snare ligature MCAo model.( A) Construction of the snare ligature. (B) Occlusion of the MCA. (C) Reflow of the MCA.
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Page 3 of 14initial concentration of 5 mg/mL using the provided
diluent (Water for Injection, USP (WFI) and further
diluted as needed to 1 mg/mL using saline for injection.
Unused portions (1 and 5 mg/mL) were divided into 1-3
mL aliquots, snap frozen and stored at -80°C [18].
Concentrations of rt-PA higher than 5 mg/mL were
not feasible because of osmolality (the 5 mg/mL solution
was 793 mOsmol/L) and solubility limitations (particu-
larly important for IA administration). The rate of test
article infusion IA or IV was 0.033-0.038 mL/min. The
experimental groups and dosing details are provided in
Table 1. A timeline of the experiment is provided in
Figure 2.
rt-PA dose administration
IA dosing
The IA dosing was accomplished by a catheter in the
EC-ICA as illustrated in Figure 3. Approximately 5
hours after MCAo, the rats were reanesthetized, intu-
bated and artificially ventilated as previously described.
The CCA, ECA, ICA and pterygopalatine arteries were
isolated by cutdown. The ECA and pterygopalatine
arteries were ligated and a catheter was introduced into
the ECA and advanced to the ICA and CCA juncture.
The catheter was secured to the ECA and the rat was
gently rolled onto his right flank and the injection port
of the catheter assembly was sutured to the left flank.
The head of the rat was immobilized as previously
described and the snare ligature was exposed. The test
article infusion was initiated and approximately 1 min-
ute later, the snare ligature was dismantled by pulling
out the 6-0 prolene, removing the silastic tubing and
cutting and removing the 10-0 suture (Figure 1C). The
surgical site was flooded with papaverine to dilate the
MCA. Reflow was confirmed by visual inspection
through the surgical microscope. Following dosing, the
EC-ICA catheter was removed, the surgical sites were
closed and the rat was returned to his home cage.
The IA dosing catheter was constructed from a PTFE
sub-lite wall tubing (SUBL-160, OD/ID 0.41/0.25 mm;
Braintree Scientific, Inc., Braintree, MA) attached to a
30 g needle which was attached to an injection port
(Additional file 1, Figure S2). To maintain patency, a
saline infusion (0.75 mL/hr) was administered as illu-
strated in Figure 3. The saline infusion was begun before
placing the catheter into the ECA to ensure no air was
infused into the ICA during the catheterization proce-
dure. For dosing, the saline syringe/butterfly infusion set
assembly was replaced with an assembly containing the
test article and the infusion pump was adjusted to the
proper rate.
Table 2 shows the blood flow in the CCA, ECA, ICA,
occipital and pterygopalatine arteries in the normal
SHR. The blood flow in the EC-ICA with all other
arteries occluded was approximately 0.89 mL/min. Thus,
the test article infusion comprised approximately 4% of
the ICA blood flow to the brain. For the 10 and 30 mg/
kg doses, the infusion rate remained the same but the
infusion duration was extended from 10 minutes to 20
and 60 minutes, respectively (See Table 1).
IV dosing
rt-PA was administered through a catheter, placed by
cutdown, in the external jugular vein. Following dosing,
the catheter was removed and the surgical sites closed.
The rats were recovered from anesthesia and returned
to their home cage. All rats received a second dose of
buprenorphine (0.03 mg/kg, subQ) during recovery from
anesthesia following the completion of dosing.
Ten (10) mg/kg IV rt-PA is considered the efficacious
dose for thrombolysis in the rat whereas the human
dose is 0.9 mg/kg. The 10-fold discrepancy is based on
an in vitro clot lysis experiment showing that rat whole
blood clots are 10 times less sensitive to human rt-PA
[19]. Recent in vivo experiments tend to support that
conclusion [20,21].
Infarct volume analysis
Twenty four hours after onset of MCAo, the rats were
deeply anesthetized with isoflurane (5% in O2)a n dt h e
brain was perfused in situ for approximately 90 seconds
Catheter 
Placement
Rats recovered in home cage
home cage
5 hours
Rats recovered in
TA Infusion 
(10-60 min) 
1 hour
MCAo
18 Hours Reflow 6 Hour Ischemia
Euthanasia
Figure 2 Experimental timeline.
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Page 4 of 14with heparinized saline (10 U/mL). The brain was
removed, placed in ice cold saline and examined for
gross superficial hemorrhage. Digital photographs of the
brain surface were obtained.
Sequential coronal sections were obtained every 2 mm
throughout the neocortex (8-9 sections/brain). The sec-
tions were stained with 1-2% 2, 3, 5 triphenyl
tetrazolium chloride (TTC) [22] at 37°C in the dark to
effect (~15 min incubation time). The sections were
fixed in 10% buffered formalin for 24 hours. Each fixed
brain section was digitally photographed with a ruled
standard.
The digital photographs of the fixed TTC stained
brain sections were imported into an image analysis
program (Image-Pro Plus v4.5, Media Cybernetics, Inc.,
Bethesda, MD) for infarct volume measurement. The
infarct volume, reported in mm
3, was determined by the
indirect method.
Bleeding score
Two complete 10 μm sections, spaced 250 μma p a r t ,
were obtained from each original 2 mm TTC stained
section and processed for H&E histopathology (16-18;
10 μm sections/rat brain). Each section was evaluated
for Bleeding Score, according to the following defini-
tions (Examples are shown in Figure 4):
0 = Normal ischemic damage - no hemorrhage
1 = Dispersed individual petechiae
2 = Confluent petechiae
3 = Hemorrhagic infarction
4 = Large cerebral hemorrhage
5 = Animal found dead due to ICH before planned
termination
5.5 = Hemorrhage to non ischemic brain tissue
T h eo v e r a l ls c o r ef o rt h er a tb r a i nw a st h eh i g h e s t
score of the evaluated sections.
Neurological function analysis
The rats were assessed for neurological function twice
during the study, once prior to the induction of anesthesia
to place the catheter for test article administration and
again just before euthanasia. The first assessment was to
screen for stroke presence; any rat not displaying a score
of at least 2 was eliminated from the study. The second
assessment was performed just before euthanasia to deter-
mine the final functional recovery of the rat; only the sec-
ond score was analyzed as an experimental variable.
The rats were assessed for neurological function using
a Modified Bederson Score [23] in an unblinded manner
by RCC and GMT with the following definitions:
Score 0: No apparent neurological deficits
Score 1: Body torsion present
Score 2: Body torsion with right side weakness
Score 3: Body torsion, right side weakness with cir-
cling behavior
Score 4: Unresponsiveness - euthanasia < 3 hours
after dosing
Figure 3 Schematic of IA dosing. For clarity, the illustration shows
a ventral analogy. In practice, once the extra-cranial internal carotid
artery (EC-ICA) was cannulated, the rat was gently rolled onto his
right flank and the injection port was secured to the left flank. The
head was, again, immobilized in the head holder. During this
process, patency of the catheter was maintained by saline infusion
(0.75 mL/hr). Infusion of test article was accomplished by replacing
the saline flush syringe butterfly assembly with an assembly
containing the test article. The infusion of the test article was
initiated approximately 1 minute before dismantling the snare
ligature while the head was secured in the head holder.
Table 2 Blood flow for the indicated arteries
Artery Blood Flow
(mL/min)
% EC-ICA
Blood Flow*
Common Carotid Artery 3.49 ± 0.19 ——
Occipital Artery 0.43 ± 0.09 ——
External Carotid Artery 1.22 ± 0.28 ——
Pterygopalatine Artery 1.52 ± 0.08 63%
Intra-Cranial Internal Carotid Artery
(blood flow to the brain)
0.89 ± 0.04 37%
The arteries were isolated by cutdown and a perivascular blood flow probe
was placed around the common carotid artery. Arteries were then
sequentially occluded and blood flow for each artery was determined by
subtraction. * Percent of the extra-cranial internal carotid artery (EC-ICA) blood
flow delivered to these arteries (the rat EC-ICA bifurcates just before entering
the skull). The values are the mean ± SEM (n = 4).
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death before scheduled termination due to ICH.
Exclusion/Inclusion criteria
Animals were excluded from the study if one of the fol-
lowing occurred: breakage of the MCA during occlusion
or recanalization; breakage of a side branch of the MCA
causing bleeding at the surgical site; Modified Bederson
Score less than 2 prior to start of the reflow surgery;
reflow cannot be visually confirmed; excessive bruising
of the brain during occlusion surgery; observation of air
bubbles or particles in the ICA catheter during infu-
sions; surgical complications requiring euthanasia, or a
plasma glucose concentration > 200 mg/dL prior to
MCAo.
Figure 4 Examples of the bleeding severity score. Two 10 μm sections were obtained from each 2 mm TTC stained section and stained with
H&E.
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Statistical analysis of the infarct volume and physiologi-
cal variables between the experimental groups was
accomplished by ANOVA followed by Tukey-Kramer
HSD multiple comparison test (JMP statistical software,
SAS Institute, Inc., Cary, NC).
Statistical analysis of the Bleeding Score and the Mod-
ified Bederson Score data was performed using the
Kruskal-Wallis one way ANOVA test for non-para-
metric data followed by Newman-Keuls multiple com-
parison test using the GBstat statistical package
(Dynamic Microsystem, Inc., Silver Spring, MD).
Analysis of covariance (ANCOVA) with the dependent
variables of infarct volume, Bleeding Score and Modified
Bederson Score, respectively, with the independent vari-
ables of dose and route was performed using SAS
® soft-
ware version 9.2 (SAS Institute, Inc. Cary, NC).
To determine the number of rats in each group, a
power analysis of the vehicle group from a contempor-
a r yp i l o ts t u d yw a sp e r f o r m e du s i n gi n f a r c tv o l u m ea s
the test variable. To observe a statistically significant dif-
ference of 30% between the means of the experimental
groups at an a level of 0.05 and a b level of 0.8, an n of
at least 5 animals would be required. This is consistent
with Brint et al [24] and with our past experience using
the SHR in stroke studies. All of the data are presented
as mean ± SEM.
The infarct volume and Bleeding Score were deter-
mined in a blinded fashion by CPT in the laboratory of
JCL (Case Western Reserve University, Cleveland, Ohio).
Preliminary control studies
Temporal infarct progression
Historical unpublished temporal progression data gener-
ated by two of the authors (RCC and JCL) at Case Wes-
tern Reserve University in Cleveland, Ohio (1987)
suggests that 6 hours of MCAo with reflow should
result in maximal large stable infarct volumes (Addi-
tional file 1, Figure S3). These data are similar to those
of Aronowski et al [25] and are consistent with the
“time is brain” concept in the clinic [26-28]. We chose a
6 hour ischemia duration to better mimic extended
symptom onset to treatment delay in the clinic and we
chose the spontaneously hypertensive rat (SHR) because
of the reproducibility of the ischemic lesion.
Sham animals
To determine the contribution of the surgical procedure
and EC-ICA saline infusion on infarct volume, two
sham groups were performed. In the first group (surgi-
cal shams, n = 3), the MCAo surgical procedure was
performed, the artery was elevated into the silastic tube
(not occluded) for less than 5 seconds and then the
snare ligature was immediately dismantled. In the sec-
ond group (ICA sham, n = 2), rats were exposed to the
surgical sham procedure followed by saline infusion into
the EC-ICA 6 hours later. No visible damage to the
brain was apparent by gross inspection of the brain or
in TTC stained or in H&E stained histological sections
(Additional file 1, Figures S4 and S5).
Reflow confirmation after 6 hours MCAo
To confirm reflow of the MCA following removal of the
snare ligature, 2 rats were subjected to 6 hours MCAo,
the EC-ICA was cannulated and within 5 minutes fol-
lowing removal of the snare ligature, pink latex was
infused into the cerebral circulation through the EC-
ICA catheter. In both rats, the latex demarked the MCA
vascular tree distal to the occlusion site, confirming
reflow (Additional file 1, Figure S6).
Results
Exclusion of animals
MCAo surgery was performed on 56 rats, of which 42
were assigned to the different experimental groups.
Exclusions were for breakage of the MCA or a side
branch (3 rats), bleeding complications prior to craniot-
omy (3 rats), bruising of brain tissue (2 rats), occlusion
device malfunction (2 rats), clot in the ICA just distal to
the pterygopalatine artery bifurcation (1 rat) and techni-
cal difficulties (3 rats).
Physiological variables
All of the physiological variables were within normal
range throughout the MCAo and reflow surgeries
(Table 3). In all groups, the plasma glucose values prior
to MCAo were significantly lower than prior to reflow;
the former values reflect fasting the rats overnight and
the latter values indicate that the rats were eating the
gel style food between the two surgeries.
Bleeding score
The Bleeding Score for the experimental groups are
shown in Figure 5. Photographs of the gross brain and a
TTC stained section of the brain at the level of the
basal ganglia and in some cases, at the level of the ante-
rior hippocampus are presented for the animals treated
with saline (Figure 6), 10 or 30 mg/kg rt-PA IA (Figures
7 and 8, respectively), and 10 or 30 mg/kg IV (Figures 9
and 10, respectively).
The Bleeding Severity Score of the saline group (1.7 ±
0.5) and the groups treated IA with 1, 5 and 10 mg/kg
rtPA were low (2.2 ± 0.4, 2.4 ± 0.3 and 2.5 ± 0.2,
respectively) and similar (Figures 5, 6 and 7). Markedly
more severe bleeding was observed with 30 mg/kg rtPA
delivered IA (4.9 ± 0.4) compared with all other groups
except 5 mg/kg IA rt-PA. One rat treated with 30 mg/
kg rt-PA IA had a massive space-occupying hemorrhage
and did not survive to the scheduled end of the experi-
ment (# 61715, Figure 8). Three rats in this group had
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Figure 8, left panels, respectively; thin arrows) resulting
in hypothalamic damage (Figure 8, right panels, respec-
tively; thick arrows). Two of these rats developed seizure
activity after dosing that necessitated euthanasia.
An increase in bleeding score occurred with increased
doses of rtPA IV (Figure 5). The 30 mg/kg IV rtPA dose
showed a higher Bleeding Score (3.1 ± 0.7) as compared
to the 10 mg/kg rtPA IV dose (1.0 ± 0.3), and space-
occupying hemorrhage occurred in 2 of 5 rats (61366
and 61368, Figure 10; right panel, respectively; thin
arrows). Four of 5 rats were euthanized approximately 3
hours after terminating anesthesia after agent adminis-
tration because of unresponsiveness. None of the rats in
this group had brain stem hemorrhage, seizure activity
or hypothalamic damage.
The 10 mg/kg IA rt-PA dose caused significantly more
bleeding than did 10 mg/kg IV (Figures 5, 7 and 9).
Indeed, rats that received only 1 or 5 mg/kg IA rt-PA
had significantly more bleeding than rats receiving 10
mg/kg rt-PA IV. Similarly, 30 mg/kg IA rt-PA caused
significantly more bleeding than did 30 mg/kg IV (Fig-
ures 5, 8 and 10). The Bleeding Score in rats receiving
30 mg/kg rt-PA IV was not significantly different that in
rats receiving 10 mg/kg rt-PA IA. Multivariate analysis
revealed a statistically significant effect of dose and
route on Bleeding Score (Table 4).
Infarct volume
The infarct volume after 6 hours of ligature ischemia
followed by 18 hours reflow was not significantly differ-
ent for all treatments (Figure 11), although there was a
trend towards a larger infarct volume using the highest
dose (30 mg/kg) of rt-PA either IA or IV. Saline treat-
ment (252 ± 41 mm
3) and treatment with 1 mg/kg IA
(264 ± 19 mm
3), 5 mg/kg IA (247 ± 23 mm
3)a n d1 0
mg/kg IA (240 ± 8 mm
3) had very similar infarct
volumes, whereas infarct volume after treatment with 30
Table 3 Physiological variables
Pre Ischemia Saline IA
(n = 5)
rt-PA: 1 mg/kg
IA (n = 5)
rt-PA: 5 mg/kg
IA (n = 7)
rt-PA: 10 mg/kg
IA (n = 5)
rt-PA: 30 mg/kg
IA (n = 5)
rt-PA: 10 mg/kg
IV (n = 5)
rt-PA: 30 mg/kg
IV (n = 5)
pH 7.43 ± 0.03 7.48 ± 0.01 7.49 ± 0.01 7.47 ± 0.02 7.46 ± 0.03 7.51 ± 0.02 7.44 ± 0.01
PaCO2 (mmHg) 39.1 ± 4.5 36.2 ± 1.0 36.2 ± 1.2 38.7 ± 1.2 38.3 ± 2.5 35.2 ± 2.1 41.3 ± 1.6
PaO2 (mmHg) 99.2 ± 6.5 118.0 ± 6.0 111.9 ± 4.0 164.6 ± 7.5 109.0 ± 8.7 110.0 ± 11.9 106.4 ± 4.5
Glu (mg/dL) 138 ± 9 137 ± 4 131 ± 8 152 ± 10 136 ± 13 139 ± 6 136 ± 13
MABP (mmHg) 116 ± 17 105 ± 7 145 ± 12 119 ± 13 148 ± 15 132 ± 10 141 ± 15
HR (beats/min) 362 ± 10 353 ± 6 332 ± 6 351 ± 12 358 ± 11 347 ± 16 334 ± 40
Hct (%PCV) 43.8 ± 1.9 45.6 ± 0.7 44.6 ± 0.6 45.6 ± 0.5 44.6 ± 0.7 45.2 ± 0.5 45.2 ± 0.5
Body Temp (°C) 37.1 ± 0.1 37.0 ± 0.0 37.1 ± 0.1 37.0 ± 0.0 37.1 ± 0.1 37.0 ± 0.0 37.1 ± 0.0
Body Wt (g) 329.0 ± 7.0 328.4 ± 6.5 345.4 ± 3.2 339.6 ± 12.7 318.2 ± 7.8 328.6 ± 14.3 330.8 ± 2.0
Pre Reflow
pH 7.47 ± 0.03 7.42 ± 0.02 7.48 ± 0.02 7.44 ± 0.01 7.45 ± 0.02 7.42 ± 0.04 7.45 ± 0.02
PaCO2 (mmHg) 34.6 ± 2.7 38.7 ± 2.0 36.6 ± 1.2 38.1 ± 1.2 37.1 ± 1.0 38.6 ± 2.6 38.9 ± 1.6
PaO2 (mmHg) 157.4 ± 2.7 167.4 ± 17.6 167.1 ± 10.2 164.6 ± 7.5 149.4 ± 12.3 145.8 ± 13.4 136.0 ± 6.6
Glu (mg/dL) 195 ± 38 348 ± 63 299 ± 49 379 ± 81 196 ± 13 243 ± 44 204 ± 11
MABP (mmHg) 145 ± 18 138 ± 16 117 ± 14 145 ± 12 137 ± 14 138 ± 19 164 ± 16
HR (beats/min) 377 ± 7 370 ± 9 347 ± 9 367 ± 7 368 ± 9 364 ± 16 340 ± 34
Hct (%PCV) 43.4 ± 2.6 46.0 ± 1.0 45.3 ± 0.7 46.4 ± 1.1 42.6 ± 1.0 45.6 ± 0.8 45.6 ± 1.0
Body Temp (°C) 37.1 ± 0.1 37.1 ± 0.0 37.0 ± 0.1 37.1 ± 0.0 37.0 ± 0.1 37.6 ± 0.4 37.0 ± 0.1
Rats were subjected to MCAo with reflow as described. Blood from the tail arterial line was obtained and analyzed for blood gas values within 5 minutes of
MCAo and of removal of the snare ligature (pre-reflow values). The values are the mean ± SEM.
Figure 5 Bleeding score.R a t sw e r es u b j e c t e dt o6h o u r sM C A o
followed by approximately 18 hours of reflow. Treatment with rt-PA
began 1 minute before reflow. The values are the mean ± SEM (n =
5, 5, 7, 5, 5, 5, 5, respectively). * p < 0.05 compared to indicated
groups (Kruskal-Wallis, Newman-Keuls). # p < 0.05 compared to 30
mg/kg rt-PA, IV (Kruskal-Wallis, Newman-Keuls).
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Page 8 of 14mg/kg rtPA IA tended to be larger (306 ± 35 mm
3).
Infarct volumes after IV rtPA at 10 and 30 mg/kg (298
±3 7a n d3 3 8±4 8m m
3, respectively) tended to be lar-
ger than saline control. Multivariate analysis showed no
statically significant effects of dose or route on infarct
volume (Table 4).
Modified Bederson score
The Modified Bederson Score, reflecting neurological
function 24 hours following MCAO (Figure 12) was
nearly identical in rats treated with saline (2.4 ± 0.24),
with IA rt-PA at 1 mg/kg (2.25 ± 0.22), 5 mg/kg (2.29 ±
0.22) and 10 mg/kg (2.38 ± 0.24) and with IV rtPA at
Figure 6 IA saline control animals. Rats were subjected to 6 hours MCAo with reflow. Treatment with IA saline commenced 1 minute before
reflow. Photographs of the gross brain and a TTC stained coronal section from each animal in the group are displayed.
Figure 7 IA rt-PA 10 mg/kg animals. Rats were subjected to 6 hours MCAo with reflow. Treatment with IA rt-PA 10 mg/kg commenced 1
minute before reflow. Photographs of the gross brain and a TTC stained coronal section from each animal in the group are displayed. Arrows
indicate hemorrhage.
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Page 9 of 1410 mg/kg (2.00 ± 0.00). In general, the rats were alert
and responsive to external stimuli and were eating and
drinking. They displayed body torsion and right side
weakness but, in most cases, circling was not present. In
contrast, rats exposed to 30 mg/kg rt-PA IA (4.30 ±
0.66) and 30 mg/kg rt-PA IV (3.60 ± 0.40) showed more
severe neurological dysfunction. Multivariate analysis
showed a significant effect of dose and route on the
Modified Bederson Score (Table 4).
Discussion
We tested the safety of IA versus IV rt-PA administra-
tion in a rat model of MCAo in an extended ischemic
time window. The main finding of the study was that rt-
PA administered by IA infusion after 6 hours of MCAo
had significantly more intracerebral bleeding than did
the same dosages administered IV. Indeed, even 1 mg/
kg rt-PA IA caused more severe bleeding than 10 times
that dose IV (10 mg/kg). The increased bleeding did not
translate into a significant increase in infarct volume.
The highest rt-PA dosage by both the IA and IV routes
resulted in increased neurological dysfunction.
The increased bleeding with IA administration prob-
ably relates to higher concentrations of rt-PA in the
local milieu. Also, rt-PA is metabolized rapidly by the
liver resulting in a biological plasma half life in the rat
of only 1-2 minutes [29], further exaggerating the differ-
ence in concentration after IV versus IA administration.
Cerebral ischemia predisposes the vasculature and sur-
rounding parenchyma to hemorrhage upon vascular
recanalization [30] and the vulnerability of the down-
stream brain parenchyma increases with longer periods
of ischemia. Several pathological mechanisms underlie
the ICH caused by rt-PA including, activation of MMP-
9, interaction with NMDA receptors, endogenous pro-
teolytic activity, injury to the endothelial junctional pro-
teins contributing to the blood-brain barrier
dysfunction, and activation of other proteolytic enzymes
such as plasmin [31]. Taken together, it is not surprising
that our results support the conclusion that similar
dosages of rt-PA delivered IA carry greater ICH risk
than when delivered IV.
The duration of the ischemic event may modify the
toxicity of rt-PA. Increased bleeding did not occur with
Figure 8 IA rt-PA 30 mg/kg animals. Rats were subjected to 6 hours MCAo with reflow. Treatment with IA rt-PA 30 mg/kg commenced 1
minute before reflow. Photographs of the gross brain and a TTC stained coronal section from each animal in the group are displayed. Thin
arrows indicate hemorrhage. Thick arrows indicate damage to the hypothalamus.
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Page 10 of 14IV rt-PA doses as high as 20 mg/kg if administered
within 1 hour ischemic onset [32], suggesting a thera-
peutic index (TI = Toxic dose ÷ Therapeutic dose) of
greater than 2. Whereas doses of rt-PA administered
after a 3 hour delay resulted in a dose-dependent (0.9, 9
and 18 mg/kg) increase in hemoglobin extravasation
[33]. By extension, in our study, 30 mg/kg rt-PA IV
resulted in significant bleeding following 6 hours of
ischemia. Taken together, our results and the data of
other groups supports the conclusion that bleeding is
Figure 9 IV rt-PA 10 mg/kg animals.R a t sw e r es u b j e c t e dt o6h o u r sM C A ow i t hr e f l o w . Treatment with IV rt-PA 10 mg/kg commenced 1
minute before reflow. Photographs of the gross brain and a TTC stained coronal section from each animal in the group are displayed. Arrows
indicate hemorrhage.
Figure 10 IV rt-PA 30 mg/kg animals. Rats were subjected to 6 hours MCAo with reflow. Treatment with IV rt-PA 30 mg/kg commenced 1
minute before reflow. Photographs of the gross brain and a TTC stained coronal section from each animal in the group are displayed. Arrows
indicate hemorrhage.
Crumrine et al. Experimental & Translational Stroke Medicine 2011, 3:10
http://www.etsmjournal.com/content/3/1/10
Page 11 of 14not induced by substantial doses of rt-PA following
s h o r tp e r i o d s( <3h o u r s )o fi s c h e m i a ,b u tt h a tt h er i s k
of bleeding increases significantly with longer intervals
of occlusion.
Because of the implications of high concentrations of
rt-PA when administered IA, we closely mimicked such
conditions by use of a snare ligature model, which
enabled us to initiate IA rt-PA immediately prior to vas-
cular recanalization. Furthermore, as fibrin degradation
products may contribute to rt-PA-associated ischemic
damage [34,35], the snare ligature model allowed us to
dissociate ischemic damage caused by rt-PA from that
caused by fibrinolytic products.
The clinical therapeutic dose of rt-PA IV for ischemic
stroke has been established at 0.9 mg/kg. The dose for
r t - P AI Aa sas t a n da l o n et r e a t m e n ti sm o r ev a r i a b l e
and ranges from 20 to 60 mg [10]. Our data suggest
that to avoid increased ICH risk by the IA route com-
pared to IV, the dose would need to be considerably
less, although such conclusions must be tempered by
the understanding that our model may not entirely
reflect the clinical state in human disease.
T h e3 0m g / k gr t - P AI Aa n dI Vd o s eg r o u p sw e r e
included in the study to provide an estimate of the
therapeutic index and to exaggerate potential bleeding
complications. In 3 of 5 rats, 30 mg/kg IA induced
spontaneous bleeding in the brain stem that was not
directly affected by the vascular ligation. All 3 rats had
damage to the hypothalamus and two of these had sei-
zure activity necessitating euthanasia. As the arterial
perforators to the brain stem come off of the Circle of
Willis prior to the branching of the MCA, significant
blood levels of rt-PA would be present in these arteries
following IA administration resulting in brain tissue
exposure to high concentrations of rt-PA over the
extended duration of administration (60 minutes).
Hemorrhagic damage to the brain stem, hypothalamic
damage and seizure activity did not occur in any animal
dosed with 30 mg/kg rt-PA IV.
In our study, the Modified Bederson Score was used
to assess the functional recovery of the rats. Our data
suggests that the final behavior of the rats was signifi-
cantly affected by both dose and route of rt-PA adminis-
tration and the major driving force was bleeding. The
infarct volume was not a major contributor to beha-
vioral function after 6 hours of ischemia.
A limitation to this study was the number of rats (4
out of 5) euthanized in the 30 mg/kg IV group because
of unresponsiveness to external stimuli for over 3 hours
following completion of the rt-PA infusion. The Bleed-
ing Score for these 4 rats were determined in brain sec-
tions after < 3 hours maturation following reflow, which
may have underestimated the true extent of bleeding.
However, 2 of the 4 rats received a score of 4 because
of large space occupying hemorrhages. The other 2 rats
h a dB l e e d i n gS c o r e so f3a n d2w h i c hw e r em o s tl i k e l y
accurate despite the shorter maturation time. This
Table 4 Analysis of Covariance (ANCOVA)
Dependent Variable Independent Variable p-Value
Bleeding Score Dose < 0.0001*
Route < 0.0001*
Infarct Volume Dose 0.1787
Route 0.2020
Modified Bederson Score Dose < 0.0001*
Route 0.0310*
Rats were subject to 6 hours of MCAo and then treated with saline or rt-PA.
The indicated dependent variables were analyzed in relation to the
independent variables.
Figure 11 Infarct volume.R a t sw e r es u b j e c t e dt o6h o u r sM C A o
followed by approximately 18 hours of reflow. Treatment with rt-PA
began 1 minute before reflow. The values are the mean ± SEM (n =
5, 5, 7, 5, 5, 5, 5, respectively). No significant differences were found
(ANOVA).
Figure 12 Neurological function score. Rats were subjected to 6
hours MCAo followed by approximately 18 hours of reflow.
Treatment with rt-PA began 1 minute before reflow. The values are
the mean ± SEM (n = 5, 5, 7, 5, 5, 5, 5, respectively). * p < 0.05
compared to indicated groups (Kruskal-Wallis, Newman-Keuls)
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Page 12 of 14suggests that the premature termination probably had
little effect on the Bleeding Score results.
The number of rats prematurely terminated in the
both of the 30 mg/kg rt-PA dose groups may have had
an impact on the infarct volume data. Of the 10 animals
in these 2 groups, 7 were euthanized within 3 hours of
dosing, thereby reducing the maturation of the infarct
following reflow to less than 3 hours as opposed to ~18
hours. In addition, one rat dosed 30 mg/kg rt-PA IA
died overnight. The lack of maturation of the infarct
volume may have resulted in an underestimate of the
true infarct volume in these rats.
The early termination of the rats in the 30 mg/kg IV
group may have lead to an under estimation of the
functional recovery of these rats. Two of the rats had
surprisingly little bleeding in relation to behavior and
thus, may have survived to scheduled termination. Sub-
sequent experience suggests that survival would have
been likely. The pronounced depressed behavior of
these rats post dosing suggests that rt-PA may have
severe intrinsic CNS depression activity at high doses.
Conclusion
The overall conclusion of the study was that rt-PA given
by IA infusion following extended ischemic insults
causes greater intracerebral bleeding than when similar
doses are administered IV. Indeed, IA dosages 10-fold
less than administered IV may still pose a greater ICH
risk. Because the model system we used was able to dis-
sociate damage caused by rt-PA from ischemic damage
and damage that may be caused by fibrinolytic degrada-
tion products, the bleeding observed in our study was
likely an intrinsic property of rt-PA. Our data highlights
the need for safer pharmacological thrombolytic agents
especially when administered after extended ischemic
durations.
Additional material
Additional file 1: Figure S1. Infarct Volume. Shows the extent of the
infarction produced by occlusion of the MCA near the near the inferior
cerebral vein (9 sequential TTC stained 2 mm fresh sections). Figure S2.
Construction of the IA infusion Catheter. Shows the IA catheter
components and the assembled catheter. Figure S3. Temporal
progression of infarct volume. Shows the time course of infarct
development in this model. Figure S4. Surgical Sham Animals (whole
brain and TTC stained photographs). Figure S5. EC-ICA Sham Animals
(whole brain and TTC stained photographs). Figure S6. Reflow as
indicated by latex infusion.
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